Redox Imbalance and Viral Infections in Neurodegenerative Diseases

Dolores Limongi and Sara Baldelli

Università Telematica San Raffaele Roma, Via di Val Cannuta, 00167 Rome, Italy

Correspondence should be addressed to Sara Baldelli; sara.baldelli@unisanraffaele.gov.it

Received 3 December 2015; Revised 7 March 2016; Accepted 10 March 2016

Academic Editor: Michael Courtney

Copyright © 2016 D. Limongi and S. Baldelli. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reactive oxygen species (ROS) are essential molecules for many physiological functions and act as second messengers in a large variety of tissues. An imbalance in the production and elimination of ROS is associated with human diseases including neurodegenerative disorders. In the last years the notion that neurodegenerative diseases are accompanied by chronic viral infections, which may result in an increase of neurodegenerative diseases progression, emerged. It is known in literature that enhanced viral infection risk, observed during neurodegeneration, is partly due to the increase of ROS accumulation in brain cells. However, the molecular mechanisms of viral infection, occurring during the progression of neurodegeneration, remain unclear. In this review, we discuss the recent knowledge regarding the role of influenza, herpes simplex virus type-1, and retroviruses infection in ROS/RNS-mediated Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS).

1. Introduction

Neurodegenerative diseases are chronic degenerative pathologies of the Central Nervous System (CNS) characterized by progressive loss of specific neurons that lead to a decline in brain functions [1–3]. Despite these pathologies having different clinical features, they possess some common hallmarks, such as the formation and deposition of aberrant protein conformers, synaptic dysfunctions, deficient autophagic processes, oxidative/nitrosative stress, and inflammation [4]. The neurodegenerative diseases present an increase of reactive oxygen species (ROS) production by mitochondria and NADPH oxidase (NOX), which seems to be responsible for tissue injury, inflammation, and neurodegeneration [5, 6].

Substantial evidence indicates that also reactive nitrogen species (RNS) play a key role in most common neurodegenerative diseases although the mechanism of nitric oxide (NO•) mediated neurodegeneration remains uncertain [7–9]. However, many studies demonstrated that NO is able to modify protein function by nitrosylation and nitrotyrosination, contribute to glutamate excitotoxicity, inhibit mitochondrial respiratory complexes, participate in organelle fragmentation, and mobilize zinc from internal stores in brain cells, contributing to neurodegeneration [10–13]. In response to increased oxidative and nitrosative stress the brain cells (i.e., microglia, astrocytes) activate redox-sensitive transcription factors, including nuclear factor-kβ (NF-kβ) and activator protein-1 (AP-1) [14, 15]. Next to this, it was also observed that the free radical increase, observed during neurodegeneration, may be also due to alteration of endogenous antioxidants. In particular, some antioxidant enzymes, such as superoxide dismutases (SODs), catalase, glutathione peroxidase, and glutathione reductase, have reduced activity in certain brain regions of AD patients [16]. Moreover, a reduction in amount of glutathione (GSH) level has been found in postmortem brain tissue from the substantia nigra of PD patients [17, 18]. Similarly, catalase and glutathione reductase activity, as well as GSH levels, were found to be significantly reduced in ALS patients [19]. Many of these antioxidant systems are regulated by nuclear factor (erythroid-derived 2)-like 2, also known as NFE2L2 transcription factor. In normal conditions, NFE2L2 is associated with Kelch-like ECH associating protein 1 (Keap1) in the cytoplasm. This bond prevents the nuclear translocation of NFE2L2 and promotes its degradation via Ubiquitin Proteasome System (UPS). On the contrary, the presence of oxidative stress can
induce the detachment between Keap1 and NFE2L2, due to the modification of the reactive cysteine in Keap1 [20]. These conformational changes determine a release of NFE2L2 and its nuclear translocation, where it binds the ARE consensus sequences and coordinates the transcription of antioxidant and phase II detoxification genes [21]. Alterations of NFE2L2-pathway have been observed in postmortem brain of patients with neurodegenerative disorders [20]. In particular, many studies have showed an increase of NFE2L2 nuclear translocation in dopaminergic neurons of PD patients, but this induction is not sufficient to counteract the oxidative stress [22]. On the contrary, a decrease of NFE2L2 expression has been observed in hippocampus neurons in AD cases [22]. Moreover, a reduction of mRNA and protein levels of NFE2L2 was also found in the motor cortex and spinal cord in ALS patients [23]. Thus, the activation of NFE2L2-ARE pathway constitutes a valuable therapeutic tool to combat oxidative stress that occurs during neurodegenerative disease.

Recently, it has been demonstrated that infection agents can reach the CNS crossing the blood-brain barrier, by infected migratory macrophage or by intraneuronal transfer from peripheral nerves [24, 25]. In particular, these infections can affect the immune system resulting in a variety of systemic signs and symptoms [26]. The virus replication into the CNS produces molecular hallmarks of neurodegeneration, such as protein misfolding, deposition of misfolded protein aggregates, alterations of autophagic pathways, oxidative stress, neuronal functional alterations, and apoptotic cell death [26–28]. These effects associated with genetic alteration and other environmental factors contribute to the pathogenesis of neurodegenerative diseases.

In this review, we will highlight the role of oxidative stress and viral infection in the pathogenesis of Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS).

2. Role of Oxidative Stress in Neurodegeneration: General Aspects

Oxidative stress occurs due to an imbalance in the prooxidant and antioxidant levels. ROS and RNS are highly reactive with biomolecules, including proteins, lipids, carbohydrate, DNA, and RNA [29]. ROS that are particularly abundant during an imbalance of redox state are superoxide anion (O$_2^{−}$), hydrogen peroxide (H$_2$O$_2$), and hydroxyl radical (‘OH), whereas among RNS the most abundant are NO and peroxynitrite (ONOO$^−$). During mitochondrial activity O$_2^{−}$ is produced in the electron transport chain (ETC), which is immediately converted to H$_2$O$_2$ by superoxide dismutase 2 (SOD2) located in the mitochondrial matrix or SOD1 located in the cytosol [30]. H$_2$O$_2$ is rapidly converted to water by mitochondrial glutathione (mtGSH) with the participation of GSH reductase and peroxiredoxins [31]. Other sources of free radical are the NOXs, enzymes located in the cell membrane. Several NOXs are expressed in the cells of CNS, such as neurons, astrocytes, and microglia [32, 33]. During infections, activation of NOXs is strongly improved and the resulting ROS increase is particularly important as a host defense mechanism [34]. However, excessive NOXs activation has also been implicated in oxidative stress-mediated neurodegeneration [35].

The brain is particularly prone to oxidative stress-induced damage because of its high oxygen demand, the abundance of redox-active metals (iron and copper), the high levels of oxidizable polyunsaturated fatty acids, and the low amounts of antioxidant enzymes (Figure 1). Another issue is that the neurons are postmitotic cells with relatively restricted replenishment by progenitor cells during the lifespan of an organism [11, 36]. Thus, the brain may be particularly vulnerable to viral infections during neurodegeneration due to different reasons: (i) the blood-barrier is compromised during neurodegeneration; (ii) many viruses can reach the CNS by peripheral nerves; (iii) the mitochondria become dysfunctional during neurodegeneration, preventing neurons from depending on aerobic metabolism and making it very susceptible to oxidative stress [17]. Primarily, in this review, the role of redox imbalance and redox-mediated inflammation in the onset and pathogenesis of neurodegenerative diseases will be discussed.

2.1. Redox Imbalance in AD. AD is a neurodegenerative disorder characterized by progressive decline in cognitive functions leading to memory loss and dementia. It involves degeneration of limbic and cortical brain structures, especially in the temporal lobe. One characteristic of AD is the appearance of senile plaques, which are produced from proteolytic cleavage of the transmembrane amyloid precursor protein (APP) to form β-amyloid peptide (Aβ). Another characteristic of AD is neurofibrillary tangles (NFTs) [37] and aggregates of medium and high molecular weight neurofilaments (NFM and NFH, resp.), as well as the microtubule-stabilizing protein tau, a multifunctional protein involved in...
oxidative stress is linked to the formation of amyloid plaques and NFTs in AD. Therefore, redox transition metals balance (i.e., iron, copper) is the major cause of neurodegeneration. However, the function of many proteins, such as ferritin and ceruloplasmin, which are important to regulation of metal homeostasis, shows altered expression in AD compared with controls [50].

Despite the cause of redox imbalance still being unclear in AD pathogenesis, many studies suggest that the alteration in redox transition metals balance (i.e., iron, copper) is the major cause of neurodegeneration [51–53]. In fact, iron and copper have been found in high concentrations in AD brain. In particular, Zn, Cu, and Fe in senile plaques rim and cores have been found significantly elevated in AD [51]. It has also been demonstrated that the activity of many proteins, such as ferritin and ceruloplasmin, which are important to regulation of metal homeostasis, shows altered expression in AD [54]. Other studies have revealed dramatic drops in the levels of some biometals in the AD brain, which may aid development of senile plaques [55]. In particular, decreased levels of intracellular Cu have been reported in cortical neurons derived from AD transgenic mice and in the most-affected brain region of AD patients [56]. This alteration appears to contribute in part to AD pathogenesis. The dysregulation of biometal homeostasis in AD is a complex pathway, which has contributed to the development of new therapeutic approaches to restore the neuronal functions.

The combination of all these factors could explain how the oxidative stress is linked to the formation of amyloid plaques and NFTs in AD.

2.2. Redox Imbalance in PD. PD is progressive neurodegenerative disease characterized by extrapyramidal movement disorders that manifest as rigidity, resting tremor, and postural instability [57]. PD is also characterized by a progressive loss of dopaminergic neurons in the substantia nigra, accompanied by the accumulation of α-synuclein aggregates in Lewy bodies [58]. Lewy bodies are composed not only of α-synuclein, but also of other proteins, such as ubiquitin and neurofilament proteins [59].

Many evidences demonstrate that oxidative stress plays an important role in PD pathogenesis. The substantiae nigrae of PD subjects show increased levels of oxidized protein lipid [60], DNA [61], and decreased level of GSH [62]. In particular, oxidized proteins may not be adequately ubiquitinated and recognized by proteasome and thus accumulate within the neurons [63]. Moreover, DNA damage could determine an alteration of many important genes essential for neurons activity and functionality [64]. Increased levels of 4-hydroxynonenal (HNE) were found in the rime of Lewy bodies of PD [65]. HNE, activating caspase-8, caspase-9, and caspase-3 and inducing DNA fragmentation, is able to ultimately provoke apoptosis of dopaminergic cells [66]. HNE inhibits NF-kB pathway [67], induces PARP cleavage [68], decrease GSH content, and inhibits complexes I and II of the ETC, contributing to the disease progression [69–71].

Mice treated with PD toxins (i.e., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat, and rotenone) support the link between oxidative stress and dopaminergic neuronal degeneration. In particular, MPTP causes a depletion of dopamine (DA) levels [72] and reduction of tyrosine hydroxylase (TH) [73]. The monoamine oxidase B (MO B) converts MPTP in 1-methyl-4-phenylpyridinium (MPP+), which blocks mitochondrial complex I and causes ATP depletion and ROS increase. This is thought to be the main cause of MPTP-induced terminal degeneration [74–77]. Consequently, MPTP-treated mice show an induction of glial response and increased levels of inflammatory cytokines and microglial activation, suggesting that the neurodegenerative process is evolving [78].

In the last years, the discovery of genes implicated to familial forms of PD (i.e., α-synuclein, Parkin, and DJ-1) has allowed the identification of new mechanisms, which highlight the importance of oxidative stress in PD pathogenesis. For example, α-synuclein gene mutations are linked with inherited PD and increase the tendency of the protein to aggregate [79]. It is a natively unfolded protein that can associate with vesicular and membranous structures and plays a role in synaptic vesicle recycling storage. Fibrils of α-synuclein in conjunction with DA were found in substantia nigra, which lead to an accumulation of cytotoxic soluble protofibrils and an increase of oxidative/nitrosative stress [80, 81].

2.3. Redox Imbalance in ALS. ALS is a relentlessly progressive neurodegenerative disorder, in which increasing muscle weakness leads to respiratory failure and death, which typically develops during the sixth or seventh decade of life [82].

Different studies show an increase of oxidative damage to proteins in ALS postmortem tissues compared to control. In particular, high levels of protein carbonyls have been identified in both spinal cord [83] and motor cortex [84] from ALS cases. Increased 3-nitrotyrosine levels were observed in both sporadic and SOD1 familial ALS patients [85]. Oxidative damage to DNA, measured by levels of 8-OHG, has also been found to be increased in cervical spinal cord from ALS patients [86]. Immunoreactivity to the brain and endothelial forms of nitric oxide synthase (eNOS) was also elevated in ALS motor neurons relative to controls, suggesting that nitrification of protein-tyrosine residue is upregulated in motor neurons of the spinal cord of ALS [87].
Transgenic mouse models and cell culture models of ALS based on mutant SOD1 recapitulate the oxidative damage to protein, lipid, and DNA observed in the human disease [88]. Moreover, many studies have suggested that SOD1 mutations could have toxic effects for three different reasons: (i) loss of function leading to increased levels of $O_2^-$, which can react with NO to produce ONOO$^-$ [85]; (ii) a dominant-negative mechanism whereby the mutant SOD1 protein not only is inactive, but also inhibits the function of normal SOD1 expressed by the normal allele [89]; or (iii) increased SOD1 activity leading to increased $H_2O_2$ levels and $\cdot OH$ [89].

A new pathological feature identified in postmortem tissue of ALS patients consists in neuronal protein deposition of TDP-43 or TAR DNA binding protein with a molecular mass of 43 kDa [90]. In particular, TDP-43 aggregates were found in 97% of ALS cases whether sporadic or familial [91, 92]. TDP-43 is a ubiquitously expressed DNA/RNA-binding protein, which is expressed in cytoplasm and in the nucleus where it regulates RNA splicing and microRNA biogenesis [93–95]. It has been observed that in conditions of oxidative stress TDP-43 is able to translocate in cytoplasm and assemble into stress granules (SGs), which are evident in ALS [96, 97]. SGs are large messenger ribonucleoprotein aggregates that are implicated in the stress-mediated inhibition of mRNA and protein synthesis [98]. An altered control of mRNA translation in stressful conditions may trigger motor neuron degeneration at early stages of the disease. Thus, the presence of TDP-43 in SGs leads to a loss of protein functionality defining an altered control of mRNA translation in stressful conditions triggering neuron degeneration.

3. Redox-Mediated Inflammation in Neurodegenerative Diseases

Recent studies have highlighted the correlation between oxidative damage and neuroinflammation in neurodegenerative processes, with the term neuroinflammation meaning the chronic inflammation of the CNS. It is characterized by inflammatory molecules expression, endothelial cell activation, platelet deposition, and tissue edema. Neuroinflammation plays an important role in many common neurodegenerative diseases [99]. Its accompanied by an increase of NO and/or $O_2^-$ with $H_2O_2$ production [100]. Generally, the inflammation is a protective process that protects the cells from detrimental agents, promoting tissue repair. In uncontrolled conditions the inflammatory process induces inordinate cell damage as it occurs in neurodegenerative disease. In particular, during neuroinflammation, microglia and astrocytes produce many inflammatory genes, including cytokines, chemokines, adhesion molecules, and proinflammatory transcription factors [101]. An increase of some transcription factors involved in inflammation was also found, such as NF-k$\bar{B}$, peroxisome proliferator-activated receptor gamma (PPAR$\gamma$), and Sp1 in microglia cultures and AD brain [102–104]. Thus, the inflammatory mediators secreted by microglial and astrocytic cells contribute to neuronal dystrophy [105]. In these conditions microglia can produce ROS, NO, and proteolytic enzyme, enhancing the senile plaques and NFTs formation [106]. Furthermore, as a vicious cycle, the senile plaques induce the expression of proinflammatory cytokines and enzymes such as inducible NOS (iNOS) and cyclooxygenase enzyme (COX-2) in microglia cells, suggesting that all these factors can contribute to neurodegeneration [107].

In the case of AD many authors speculate that senile plaques and NFTs constitute the site of activation of a chronic inflammatory response. In fact, an interaction between $\alpha$-peptide and CR3/Mac-1 (CD11b/CD18) on microglia has been observed. This interaction determines the activation of phosphatidylinositol 3-kinase (PI3K), which in turn phosphorylates p47$^{phox}$, inducing the PHOX translocation and activation on microglia membrane increasing the production of $O_2^-$ and causing neuroinflammation [108, 109]. Thus the abnormal activation of microglia disrupts nerve terminals activity causing an alteration and a loss of synapses, which correlates with memory decline, leading to progression of AD [110]. Next to this, some studies have revealed an association between AD and mutations in different genes opening new strategies for comprehension of pathology [111, 112]. For example, genome exome and Sanger sequencing have revealed that heterozygous rare variants in triggering receptor expressed on myeloid cells 2 (TREM2) are associated with a significant increase in the risk of AD [113]. Also genome-wide investigations have revealed many polymorphisms in the human genome of AD patients. In particular, polymorphisms on clusterin (ApoJ, a potent regulator of complement induction) and CR1 (complement receptor) genes are genetically associated with sporadic AD [114, 115]. Moreover, the single nucleotide polymorphisms for cytokines and chemokines genes have been associated with AD risk [116]. In PD the activation of microglia has been amply demonstrated, suggesting an important role of neuroinflammation in the pathophysiology of PD. Activated microglia produce $O_2^-$ and NO, which in turn contribute to oxidative and nitrosative stress in the brain [117]. Notably, activated microglia and T lymphocytes, together with an increase of proinflammatory mediators, have been detected in the brain and cerebrospinal fluids of PD patients [118]. An increase of iNOS has been also revealed in activated microglia of PD subjects [118]. Moreover, the role of DA as being responsible for the ROS-mediated inflammation reaction in neurons was shown [119]. In fact, DA is stable in synaptic vesicles inside the cell; however once DA exists it is easily metabolized by MO. Alternatively, DA can undergo autooxidation determining the ROS production. As a result the microglia became active and produce proinflammatory cytokine, such as interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-\(\alpha\)) [120], and $O_2^-$ and NO [121], leading the generation of vicious cycle that further increases dopaminergic toxicity in the substantia nigra.

As for the other neurodegenerative diseases a characteristic of ALS pathology is the occurrence of a neuroinflammation, which activates microglia, astrocytes, and T-cells. In particular, the autopsy studies have demonstrated a microglia activation and an induction of activator transcription-3 (STAT3) in ALS spinal cord microglia [122]. Moreover,
an upregulation of lipopolysaccharide/Toll Like Receptor 4 (LPS/TLR4) signaling associated genes has been observed in peripheral blood mononuclear cell (PMBCs) from ALS patients, suggesting chronic monocytes and macrophage activations [123]. Studies made on serum and cerebrospinal fluid (CSF) of 20 ALS patients show an increase of MCP1 and IL-8 levels, indicating a stimulation of proinflammatory cytokine cascade after microglia activation [124]. Also increased levels of IL-17, IL-6, and LPS are found in the serum of subjects with ALS [125]. ELISA assays have also demonstrated an increase of IL-15 and IL-12 in serum and CSF of 21 patients with ALS, suggesting that these molecules could be used as potential markers of immune activation in ALS [126]. Moreover, 2D gel electrophoresis analysis highlighted an increased activity of components of complement C3 in serum of ALS patients with respect to controls [127]. All these studies demonstrate the presence of an inflammatory and immune response in subjects with ALS.

4. Viral Infections and Neurodegeneration

As mentioned above, a common feature of neurodegenerative disease is the chronic neuroinflammation and activation of microglia in the brains of patients with PD, AD, and ALS. In the last years, many studies show an association between virus infection and neurodegenerative as another important common feature of these disorders (Figure 2). In the second part of this review we will provide a detailed picture of how some virus infections can guide us to underpin mechanisms in neurodegeneration and amplify the damage mediated by oxidative stress.

Neuronal degeneration can be either directly or indirectly affected by viral infection. Viruses can injure neurons by direct killing, by cell lysis, and by inducing apoptosis. Different pathogens and/or their products may directly induce long-term degenerative effects, such as the deposit of misfolded protein aggregates, increased levels of oxidative stress, deficient autophagic processes, synaptopathies, and neuronal death. Viruses, bacteria, protozoa, and unconventional pathogens such as prion proteins have the ability to invade the CNS as described by De Chiara et al. (2012) [128]. There are different routes of entry of infectious agents into the CNS and they cause acute infections, which in some cases may be fatal or which may progress to become chronic illnesses [129, 130]. When the viruses enter into the nervous system, that is, they are neurotropic, it leads to activation of both innate and adaptive immune responses. Viral antigens preferentially activate the TLRs 3, 7, and 8 driving innate and adaptive immune responses and leading to neuronal damage, which occurs through direct damage, killing, release of free radicals, cellular activation, and inflammation, and induce a number of encephalopathies [58]. In particular, one of the secondary consequences of these encephalopathies can be the Parkinsonism that is both transient and permanent condition.

According to reviewed literature, and as discussed in depth below, a large number of studies demonstrate that the viruses are one of the main causes of degenerative diseases. In particular, as emerging from the review below, a growing interest is devoted to investigating the effects of H1N1 in PD (Section 4.1), of HSV1 in AD (Section 4.2), and of retroviruses in ALS (Section 4.3).

4.1. H1N1 in PD. In the last years, it has emerged that influenza virus has been implicated as a direct and an indirect cause of PD, although it was recently found that influenza...
can be considered as PD-like symptoms such as tremor, particularly in the month after an infection, but not with an increased risk of developing idiopathic PD [131].

Influenza virus is a respiratory pathogen contagious to humans, belonging to Orthomyxoviridae family, which are negative sense, single-stranded, segmented RNA viruses. In particular, a viral etiology for PD is based largely on epidemiological studies indicating a possible coincidence of PD with influenza flu pandemics, most notably the 1918-1919 "Spanish" influenza outbreak [132, 133]. In recent studies, Rohn and Catlin have shown the presence of influenza A virus within the substantia nigra pars compacta (SNpc) from postmortem PD brain sections [134]. They also identified colocalized influenza A and immune cells with caspase-cleaved Beclin-1 within the SNpc, which clearly indicated the role of neuroinflammation with influenza A virus's involvement in PD pathogenesis. Influenza A virus labelling was identified within neuromelanin granules as well as on tissue macrophages in the SNpc [134]. As mentioned above, the PD hallmark Lewy bodies are also composed mainly of aggregated α-synuclein. The formation of Lewy bodies is due to accumulation of normally produced Ser-129 phosphorylated α-synuclein [135]. It is demonstrated that H5NI influenza virus progresses from the peripheral nervous system into the CNS and increases the phosphorylation and aggregation of α-synuclein [136]. Reviewed data suggest that influenza virus could have a role in the PD.

4.2. HSV1 in AD. Growing epidemiological and experimental evidence suggests that recurrent herpes simplex virus type-1 (HSV-1) infection is a risk factor for AD. It belongs to the family Herpesviridae, which is a large family of double-stranded DNA viruses. HSV-1 is a virus that primarily infects epithelial cells of oral and nasal mucosa [137]. The concept of a viral role in AD, specifically of HSV-1, was first proposed several decades ago [138, 139]. Several epidemiological studies have reported the presence of the HSV-1 genome in postmortem brain specimens from numerous AD patients, particularly those who carry the type 4 allele of the gene that encodes apolipoprotein E (APOE4), another potential risk factor for AD [140, 141]. Moreover, Wozniak et al. [142] have found the HSV-1 DNA in amyloid plaques of AD brains.

Several studies suggest that HSV-1 could be a possible major cause of amyloid plaques and hence possible aetiological factor in AD. Besides, genes related to HSV-1 reactivation have been detected in the brain of patients with familial AD, associated with β-amyloid deposits [143]. HSV-1 infection has also been shown to promote neurotoxic Aβ accumulation [144-146], tau phosphorylation [147], and cleavage [142] in vitro. Several studies have sought anti-HSV-1 IgM as well as IgG in serum from AD patients, showing that the risk of AD is increased in elderly subjects with positive titers of anti-HSV-1 IgM antibodies [148]. Genetic studies too have linked various pathways in AD with those occurring in HSV-1 infection [149].

The presented evidences suggest that HSV1 may have a critical role in AD pathogenesis.

4.3. Retroviruses in ALS. Retroviruses play an important role in the pathogenesis of ALS. In fact, several studies have reported retroviruses to be involved in ALS [150-154]. As found by [155], the reverse transcriptase (RT) enzyme of the retroviruses can convert RNA into complementary DNA. The first demonstration of retroviral involvement in ALS dates back to 1975 when Viola et al. [156] found RT activity in cytoplasmic particulate fraction from two Guamanian ALS but not in brains from two control individuals. At that time, a growing interest was in finding the retroviral.

Other studies showed that the RT is present more frequently in ALS patients’ sera compared to that of control and the levels of the activity in ALS patients were comparable to that in HIV-infected patients [157, 158].

ALS-like syndromes are developed in a small percentage of persons infected with the human immunodeficiency virus-1 (HIV-1) or human T-cell leukemia virus-1 (HTLV-1). HIV-infected patients may develop neurological manifestations that resemble classical ALS although it occurs at a younger age and they may show a dramatic improvement following the initiation of antiretroviral therapy. On the other hand, HTLV-I associated ALS-like syndrome has several features that may distinguish it from classical ALS. However, most patients with probable or definite ALS show no evidence of HIV-1 or HTLV-1 infection [159]. Moreover, studies have shown increased HERV-K expression in both serum and brain tissue in ALS patients [160]. Furthermore, in a recent study it has been shown that HERV-K is activated in a subpopulation of patients with ALS and that its envelope protein may contribute to neurodegeneration [161]. These evidences suggest that retroviruses are involved in the pathophysiology of ALS.

5. Viral Infections and Oxidative Stress in Neurodegenerative Disease

Frequently viral infections cause changes in the redox state in host cells [162-166]. Many viral infections can cause an increased generation of ROS and RNS, which can be caused by both direct effects of virus on cells and inflammatory responses of the chronic viral host. In the presence of surplus ROS, the pathogen-mediated proteins can induce pathologic changes in neural tissue and lead to chronic inflammation of the brain, as seen in classical neurodegenerative diseases.

5.1. HSV1. HSV1-1 when infecting neurons and glia cells induce the production of proinflammatory cytokines produced by microglia and infiltrating macrophages, as well as the production of chemokines and antiviral cytokines [167, 168]. Several studies have shown that during HSV-1 infection into the cell a depletion of GSH, the production of ROS, the induction of mitochondrial DNA damage, and endoplasmatic reticulum stress with consequent alteration of the intracellular redox state towards a prooxidant state occur [166, 169-171].

More data indicate that virus infection induced oxidative damage in the brain. In particular, Schachtele et al. (2010) [172] have shown that HSV-1 induced neural cell oxidative tissue damage and cytotoxicity, which are mediated by microglial cell through a TLR2-dependent mechanism. In other studies increases in ROS levels, lipid peroxidation, and
protein nitrosylation were reported when there is HSV-1 infection [167, 173, 174]. Furthermore, in the recent study Santana et al. (2013) have shown that oxidative stress enhances the accumulation of intracellular Aβ and the inhibition of Aβ secretion induced by HSV-1 infection [175]. Several studies suggest that HSV-1 induced oxidative stress in neuronal cells may trigger β- and γ-secretase activation and, consequently, APP processing and Aβ formation. These findings demonstrate that HSV-1 infection of neuronal cells can generate multiple APP fragments with well-documented neurotoxic potentials [177].

5.2. Influenza Virus. Influenza virus uses host cell structures and metabolic pathways for its life-cycle. In particular, intracellular redox state changes, for example, GSH depletion or ROS or RNS increase, have been detected during influenza virus infection [165]. On the other hand, it has been recently demonstrated that NOX4 enzyme, the main source of ROS production during influenza virus infection, regulates specific steps of virus life-cycle [34]. Virus-induced GSH decrease is pivotal for viral replication by allowing the folding and maturation of viral hemagglutinin [176] and activating cellular kinases involved in nucleocytoplasmic traffic of viral proteins [177].

On the basis of these evidences it can be assumed that the infection of influenza virus amplifies the effects of oxidative stress, which contribute to neuronal damage.

5.3. Retroviruses. Garaci et al. [178] demonstrated that in vitro HIV infection significantly decreases the GSH content of human macrophages. In addition, recent work has shown that HIV-1 induces ROS production in astrocytes and microglia [179, 180]. Dasuri et al. [180] have shown that oxidative stress is involved in the pathology of HIV-associated neurocognitive disorders. HIV-infected monocytes and T-cell, to enter in the cell, use the glycoprotein gp120. The viral protein gp120 can directly induce apoptosis in neurons and increase oxidative stress through GSH and lipid peroxidation [179].

The increases of ROS plays a role in viral pathogenesis probably because the increase of oxidative stress, generated when viruses infect the aged neuronal cells, may contribute to increasing the production of misfolded proteins and hence to the pathogenesis of neurodegenerative diseases.

Data discussed in this review suggest that viruses can be causative agents or, at least, cofactors of some neurodegenerative diseases. Therefore, much attention should be paid to infectious and, especially, viral agents among the environmental factors contributing to neurodegenerative diseases.

6. Conclusions

Although numerous studies have been made to understand the genetic/molecular mechanisms that underly the different neurodegenerative diseases, the comprehension of how redox imbalance is implicated in viral infection during neuronal damage is still unclear. In particular, understanding whether the redox imbalance is the cause or the effect of an increased propensity of brain cells to infection would be of great importance to develop new therapeutic strategies to target redox/inflammatory markers in brain inflammation and neurodegenerative disorders.

Abbreviations

MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MPP+: 1-Methyl-4-phenylpyridinium
HNE: 4-Hydroxynonenal
8-OHG: 8-Hydroxyguanosine
AP-1: Activator protein-1
STAT3: Activator transcription-3
AGE: Advanced glycation end product
AD: Alzheimer’s disease
APP: Amyloid precursor protein
ALS: Amyotrophic lateral sclerosis
Aβ: β-Amyloid peptide
CNS: Central Nervous System
CSF: Cerebrospinal fluid
CRI: Complement receptor
COX-2: Cyclooxygenase enzyme
DAT: DA transporter
DOPAC: Dihydroxyphenylacetic acid
DA: Dopamine
ETC: Electron transport chain
eNOS: Endothelial nitric oxide synthase
GSH: Glutathione
HO-1: Heme Oxygenase-1
HSV-1: Herpes simplex virus type-1
H2O2: Hydrogen peroxide
*OH: Hydroxyl radical
IL-12: Interleukin-12
IL-15: Interleukin-15
IL-17: Interleukin-17
IL-1β: Interleukin-1β
IL-6: Interleukin-6
IL-8: Interleukin-8
iNOS: Inducible nitric oxide synthase
INF-γ: Interferon-γ
LPS: Lipopolysaccharide
MIPα: Macrophage inflammatory protein α
MIPβ: Macrophage inflammatory protein β
NFM, NFH: Medium and high molecular weight neurofilaments
mtGSH: Mitochondrial glutathione
MO B: Monoamine oxidase B
MCP1: Monocyte chemotactic protein 1
NOX: NADPH oxidase
NFTs: Neurofibrillary tangles
NO: Nitric oxide
NF-kβ: Nuclear factor-kβ
PD: Parkinson’s disease
PPARγ: Peroxisome proliferator-activated receptor gamma
ONOO−: Peroxynitrite
PMBCs: Peripheral blood mononuclear cells
RNS: Reactive nitrogen species
ROS: Reactive oxygen species
SNpc: Substantia nigra pars compacta
O$_2^-$: Superoxide anion
SOD$_2$: Superoxide dismutase 2
TLR: Toll Like Receptor
TNF-α: Tumor necrosis factor-α
TREM2: Triggering receptor expressed on myeloid cells 2
TH: Tyrosine hydroxylase.

Competing Interests
The authors have no competing interests to declare.

Authors’ Contributions
Dolores Limongi and Sara Baldelli equally contributed to this work.

References
[1] B. Halliwell, "Oxidative stress and neurodegeneration: where are we now?" *Journal of Neurochemistry*, vol. 97, no. 6, pp. 1634–1658, 2006.
[2] P. M. Carvey, A. Punati, and M. B. Newman, "Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis," *Cell Transplantation*, vol. 15, no. 3, pp. 239–250, 2006.
[3] N. Shahani, S. Subramaniam, T. Wolf, C. Tackenberg, and R. Brandt, "Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices," *The Journal of Neuroscience*, vol. 26, no. 22, pp. 6103–6114, 2006.
[4] K. A. Jellinger, "Basic mechanisms of neurodegeneration: a critical update," *Journal of Cellular and Molecular Medicine*, vol. 14, no. 3, pp. 457–487, 2010.
[5] S. Gandhi and A. Y. Abramov, "Mechanism of oxidative stress in neurodegeneration," *Oxidative Medicine and Cellular Longevity*, vol. 2012, Article ID 428010, 11 pages, 2012.
[6] Q. Wang, L. Qian, S.-H. Chen et al., "Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models," *Brain*, vol. 138, no. 5, pp. 1247–1262, 2015.
[7] J. K. Andersen, K. J. A. Davies, and H. J. Forman, "Reactive oxygen and nitrogen species in neurodegeneration," *Free Radical Biology and Medicine*, vol. 62, pp. 1–3, 2013.
[8] J. E. Yuste, E. Tarragon, C. M. Campuzano, and F. Ros-Bernal, "Implications of glial nitric oxide in neurodegenerative diseases," *Frontiers in Cellular Neuroscience*, vol. 9, article 322, 2015.
[9] S. Aras, G. Tanriover, M. Aslan, P. Yargicoglu, and A. Agar, "The role of nitric oxide on visual-evoked potentials in MPTP-induced Parkinsonism in mice," *Neurochemistry International*, vol. 72, no. 1, pp. 48–57, 2014.
[10] A. B. Knott and E. Bossy-Wetzel, "Nitric oxide in health and disease of the nervous system," *Antioxidants and Redox Signaling*, vol. 11, no. 3, pp. 541–554, 2009.
[11] K. Aquilano, S. Baldelli, G. Rotilio, and M. R. Ciriolo, "Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols," *Neurochemical Research*, vol. 33, no. 12, pp. 2416–2426, 2008.
[12] E. J. Nelson, J. Connolly, and P. McArthur, "Nitric oxide and N-nitroso compounds: excitotoxic and cell signaling mechanism," *Biology of the Cell*, vol. 95, no. 1, pp. 3–8, 2003.
[13] J. D. Marks, C. Boriboun, and J. Wang, "Mitochondrial nitric oxide mediates decreased vulnerability of hippocampal neurons from immature animals to NMDA," *The Journal of Neuroscience*, vol. 25, no. 28, pp. 6561–6575, 2005.
[14] R. von Bernhardi and J. Eugenín, "Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms," *Antioxidants and Redox Signaling*, vol. 16, no. 9, pp. 974–1031, 2012.
[15] V. Chiurchiú and M. Maccarrone, "Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities," *Antioxidants and Redox Signaling*, vol. 15, no. 9, pp. 2605–2641, 2011.
[16] A. Klugman, D. P. Naughton, M. Isaac, I. Shah, A. Petroczi, and N. Tabet, "Antioxidant enzymatic activities in alzheimer's disease: the relationship to acetylcholinesterase inhibitors," *Journal of Alzheimer's Disease*, vol. 30, no. 3, pp. 467–474, 2012.
[17] M. Smeyne and R. J. Smeynen, "Glutathione metabolism and Parkinson's disease," *Free Radical Biology and Medicine*, vol. 62, pp. 13–25, 2013.
[18] E. Sofic, K. W. Lange, K. Jellinger, and P. Riederer, "Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease," *Neuroscience Letters*, vol. 142, no. 2, pp. 128–130, 1992.
[19] G. N. Babu, A. Kumar, R. Chandra et al., "Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease," *Neurochemistry International*, vol. 52, no. 6, pp. 1284–1289, 2008.
[20] H. Yamazaki, K. Tanji, K. Wakabayashi, S. Matsuura, and K. Itoh, "Role of the Keap1/Nrf2 pathway in neurodegenerative diseases," *Pathology International*, vol. 65, no. 5, pp. 210–219, 2015.
[21] H. K. Bryan, A. Olayanju, C. E. Goldring, and B. K. Park, "The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation," *Biochemical Pharmacology*, vol. 85, no. 6, pp. 705–717, 2013.
[22] C. P. Ramsey, C. A. Glass, M. B. Montgomery et al., "Expression of Nrf2 in neurodegenerative diseases," *Journal of Neuropathology and Experimental Neurology*, vol. 66, no. 1, pp. 75–85, 2007.
[23] A. Sarlette, K. Krampfl, C. Grothe, N. V. Neuhoff, R. Denger, and S. Petri, "Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis," *Journal of Neuropathology and Experimental Neurology*, vol. 67, no. II, pp. 1055–1062, 2008.
[24] M. P. Mattson, "Infectious agents and age-related neurodegenerative disorders," *Aging Research Reviews*, vol. 3, no. 1, pp. 105–120, 2004.
[60] D. A. Bosco, D. M. Fowler, Q. Zhang et al., “Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization,” Nature Chemical Biology, vol. 2, no. 5, pp. 249–253, 2006.

[61] Y. Nakabeppu, D. Tsuchimoto, H. Yamaguchi, and K. Sakumi, “Oxidative damage in nucleic acids and Parkinson’s disease,” Journal of Neuroscience Research, vol. 85, no. 5, pp. 919–934, 2007.

[62] G. D. Zeevalk, R. Razmpour, and L. P. Bernard, “Glutathione and Parkinson’s disease: is this the elephant in the room?” Biomedicine and Pharmacotherapy, vol. 62, no. 4, pp. 236–249, 2008.

[63] E. Emmanouilidou, L. Stefanis, and K. Vekrellis, “Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome,” Neurobiology of Aging, vol. 31, no. 6, pp. 953–968, 2010.

[64] F. Coppedé and L. Migliore, “DNA damage in neurodegenerative diseases,” Mutation Research, vol. 776, pp. 84–97, 2015.

[65] R. J. Castellani, G. Perry, S. L. Siedlake et al., “Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans,” Neuroscience Letters, vol. 319, no. 1, pp. 25–28, 2002.

[66] K. E. McElhanon, C. Bose, R. Sharma, L. Wu, Y. C. Awasthi, and S. P. Singh, “4 null mouse embryonic fibroblasts exhibit enhanced sensitivity to oxidants: role of 4-hydroxynonenal in oxidant toxicity,” Open Journal of Apoptosis, vol. 02, no. 01, pp. 1–11, 2013.

[67] S. J. Lee, K. W. Seo, M. R. Yun et al., “4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the Akt/NF-kB signaling pathways,” Free Radical Biology and Medicine, vol. 45, no. 10, pp. 1487–1492, 2008.

[68] Z. F. Peng, C. H. V. Koh, Q. T. Li et al., “Deciphering the mechanism of HNE-induced apoptosis in cultured marine cortical neurons: transcriptional responses and cellular pathways,” Neuropharmacology, vol. 53, no. 5, pp. 687–698, 2007.

[69] A. Ayala, M. F. Muñoz, and S. Argüelles, “Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 360438, 31 pages, 2014.

[70] S. Camandola, G. Poli, and M. P. Mattson, “The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor κB in neurons,” Molecular Brain Research, vol. 85, no. 1-2, pp. 53–60, 2000.

[71] S. Camandola, G. Poli, and M. P. Mattson, “The lipid peroxidation product 4-hydroxy-2,3-nonenal increases AP-1-binding activity through caspase activation in neurons,” Journal of Neurochemistry, vol. 74, no. 1, pp. 159–168, 2000.

[72] Z. Guo, S. Xu, N. Du, J. Liu, Y. Huang, and M. Han, “Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson’s disease: involvement of the dopamine system,” Neuroscience Letters, vol. 616, pp. 152–159, 2016.

[73] O. von Bohlen Und Halbach, A. Schober, R. Hertel, and K. Unsicker, “MPTP treatment impairs tyrosine hydroxylase immunopositive fibers not only in the striatum, but also in the amygdala,” Neurodegenerative Diseases, vol. 2, no. 1, pp. 44–48, 2005.

[74] R. Betarbet, T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre, “Chronic systemic pesticide exposure reproduces features of Parkinson’s disease,” Nature Neuroscience, vol. 3, no. 12, pp. 1301–1306, 2000.

[75] W. Dauer and S. Przedborski, “Parkinson’s disease: mechanisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003.

[76] J. Lotharius and K. L. O’Malley, “The Parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity,” The Journal of Biological Chemistry, vol. 275, no. 49, pp. 38581–38588, 2000.

[77] T. G. Hastings, “The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 469–472, 2009.

[78] V. Jackson-Lewis and R. J. Smyne, “MTPP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview,” Neurotoxicology Research, vol. 7, no. 3, pp. 193–201, 2005.

[79] C. Proukakis, C. G. Dudzik, T. Brier et al., “A novel α-synuclein missense mutation in Parkinson disease,” Neurology, vol. 80, no. 11, pp. 1062–1064, 2013.

[80] K. A. Conway, J.-C. Rochet, R. M. Bieganski, and P. T. J. Lansbury, “Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct,” Science, vol. 294, no. 5545, pp. 1346–1349, 2001.

[81] J.-C. Rochet, T. F. Outeiro, K. A. Conway et al., “Interactions among α-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson’s disease,” Journal of Molecular Neuroscience, vol. 23, no. 1-2, pp. 23–33, 2004.

[82] V. Swarup and J.-P. Julien, “ALS pathogenesis: recent insights from genetics and mouse models,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 2, pp. 363–369, 2011.

[83] I. Niebrój-Dobosz, D. Dziewulska, and H. Kwiecienśki, “Oxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis (ALS),” Folia Neuropathologica, vol. 42, no. 3, pp. 151–156, 2004.

[84] D. Liu, F. Bao, J. Wen, and J. Liu, “Mutation of superoxide dismutase elevates reactive species: comparison of nitration and oxidation of proteins in different brain regions of transgenic mice with amyotrophic lateral sclerosis,” Neuroscience, vol. 146, no. 1, pp. 255–264, 2007.

[85] D. A. Drechsel, A. G. Estévez, L. Barbeito, and J. S. Beckman, “Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS,” Neurotoxicology Research, vol. 22, no. 4, pp. 251–264, 2012.

[86] M. Bogdanov, R. H. Brown Jr., W. Matson et al., “Increased oxidative damage to DNA in ALS patients,” Free Radical Biology and Medicine, vol. 29, no. 7, pp. 652–658, 2000.

[87] K. Abe, L.-H. Pan, M. Watanabe, H. Konno, T. Kato, and Y. Itoyama, “Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis,” Neurosci. Lett., vol. 316, pp. 236–242, 2002.

[88] V. Jackson-Lewis and R. J. Smeyne, “MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview,” Neurotoxicology Research, vol. 7, no. 3, pp. 193–201, 2005.

[89] M. Bogdanov, R. H. Brown Jr., W. Matson et al., “Increased oxidative damage to DNA in ALS patients,” Free Radical Biology and Medicine, vol. 29, no. 7, pp. 652–658, 2000.

[90] Y. Hayashi, K. Homma, and H. Ichijo, “SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS,” Advances in Biological Regulation, vol. 60, pp. 95–104, 2016.
spinal cord,” *Acta Neuropathologica*, vol. 128, no. 3, pp. 423–437, 2014.

[91] I. R. A. Mackenzie, E. H. Bigio, P. G. Ince et al., “Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations,” *Annals of Neurology*, vol. 61, no. 5, pp. 427–434, 2007.

[92] S. Maekawa, P. N. Leigh, A. King et al., “TDP-43 is consistently co-localized with ubiquitinclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations,” *Neuropathology*, vol. 29, no. 6, pp. 672–683, 2009.

[93] M. J. Winton, L. M. Igaz, M. M. Wong, L. K. Kwong, J. Q. Trojanowski, and V. M.-Y. Lee, “Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation,” *The Journal of Biological Chemistry*, vol. 283, no. 19, pp. 13302–13309, 2008.

[94] R. I. Gregory, K.-P. Yan, G. Amuthan et al., “The Microprocessor complex mediates the genesis of microRNAs,” *Nature*, vol. 432, no. 7014, pp. 235–240, 2004.

[95] Z.-S. Xu, “Does a loss of TDP-43 function cause neurodegeneration?” *Molecular Neurodegeneration*, vol. 7, article 27, 2012.

[96] L. Liu-Yesucevitz, A. Bilgutay, Y.-J. Zhang et al., “Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue,” *PloS ONE*, vol. 5, no. 10, Article ID e13250, 2010.

[97] E. Bentmann, M. Neumann, S. Tahirovic, R. Rodde, D. Dormann, and C. Haass, “Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43),” *The Journal of Biological Chemistry*, vol. 287, no. 27, pp. 23079–23094, 2012.

[98] C. Colombrita, E. Zennaro, C. Fallini et al., “TDP-43 is recruited to stress granules in conditions of oxidative insult,” *Journal of Neurochemistry*, vol. 111, no. 4, pp. 1051–1062, 2009.

[99] T. C. Frank-Cannon, L. T. Alto, F. E. McAlpine, and M. G. Tansey, “Does neuroinflammation fan the flame in neurodegenerative diseases?” *Molecular Neurodegeneration*, vol. 4, article 47, 2009.

[100] G. C. Brown, “Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase,” *Biochemical Society Transactions*, vol. 35, no. 5, pp. 1119–1121, 2007.

[101] G. Cappellano, M. Carecchio, T. Fleetwood et al., “Immunity and inflammation in neurodegenerative diseases,” *American Journal of Neurodegenerative Disease*, vol. 2, no. 2, pp. 89–107, 2013.

[102] B. A. Citron, J. S. Dennis, R. S. Zeitlin, and V. Echeverria, “Transcription factor Sp1 dysregulation in Alzheimer’s disease,” *Journal of Neuroscience Research*, vol. 86, no. 11, pp. 2499–2504, 2008.

[103] Q. Jiang, M. Heneka, and G. E. Landreth, “The role of peroxisome proliferator-activated receptor-γ (PPARγ) in Alzheimer’s disease: therapeutic implications,” *CNS Drugs*, vol. 22, no. 1, pp. 1–14, 2008.

[104] I. Granic, A. M. Dolga, I. M. Nijholt, G. Van Dijk, and U. L. M. Eisel, “Inflammation and NF-κB in Alzheimer’s disease and diabetes,” *Journal of Alzheimer’s Disease*, vol. 16, no. 4, pp. 809–821, 2009.

[105] T. Town, V. Nikolic, and J. Tan, “The microglial ‘activation’ continuum: from innate to adaptive responses,” *Journal of Neuroinflammation*, vol. 2, article 24, 2005.

[106] G. Halliday, S. R. Robinson, C. Shepherd, and J. Kril, “Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms,” *Clinical and Experimental Pharmacology and Physiology*, vol. 27, no. 1-2, pp. 1–8, 2000.

[107] G. C. Brown and A. Bal-Price, “Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria,” *Molecular Neurobiology*, vol. 27, no. 3, pp. 325–355, 2003.

[108] R. Strohmeyer, M. Ramirez, G. J. Cole, K. Mueller, and J. Rogers, “Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer’s disease brain,” *Journal of Neuroimmunology*, vol. 131, no. 1-2, pp. 135–146, 2002.

[109] D. Zhang, X. Hu, L. Qian et al., “Microglial MAC1 receptor and PI3K are essential in mediating β-amylloid peptide-induced microglial activation and subsequent neurotoxicity,” *Journal of Neuroinflammation*, vol. 8, no. 1, article 3, 2011.

[110] F.-S. Shie and R. L. Woltjer, “Manipulation of microglial activation as a therapeutic strategy in Alzheimer’s disease,” *Current Medicinal Chemistry*, vol. 14, no. 27, pp. 2865–2871, 2007.

[111] K. Bettens, K. Sleeegers, and C. Van Broeckhoven, “Genetic insights in Alzheimer’s disease,” *The Lancet*, vol. 12, no. 1, pp. 92–104, 2013.

[112] C. M. Karch, C. Cruchaga, and A. M. Goate, “Alzheimer’s disease genetics: from the bench to the clinic,” *Neuron*, vol. 83, no. 1, pp. 11–26, 2014.

[113] R. Guerreiro, A. Wojtas, J. Bras et al., “TREM2 variants in Alzheimer’s disease,” *The New England Journal of Medicine*, vol. 368, no. 2, pp. 117–127, 2013.

[114] D. Harold, R. Abraham, P. Hollingworth et al., “Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease,” *Nature Genetics*, vol. 41, no. 10, pp. 1088–1093, 2009.

[115] J.-C. Lambert, S. Heath, G. Even et al., “Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease,” *Nature Genetics*, vol. 41, no. 10, pp. 1094–1099, 2009.

[116] M. Reale, N. H. Greig, and M. A. Kamal, “Peripheral chemokine profiles in Alzheimer’s and Parkinson’s diseases,” *Mint-Reviews in Medicinal Chemistry*, vol. 9, no. 10, pp. 1229–1241, 2009.

[117] L. Qian and P. M. Flood, “Microglial cells and Parkinson’s disease,” *Immunologic Research*, vol. 41, no. 3, pp. 153–164, 2008.

[118] E. C. Hirsch, T. Breidelert, E. Rousselet, S. Hunot, A. Hartmann, and P. P. Michal, “The role of glial reaction and inflammation in Parkinson’s disease,” *Annals of the New York Academy of Sciences*, vol. 991, pp. 214–228, 2003.

[119] J. Segura-Aguilar, I. Paris, P. Muñoz, E. Ferrari, L. Zecca, and F. A. Zacca, “Protective and toxic roles of dopamine in Parkinson’s disease,” *Journal of Neurochemistry*, vol. 129, no. 6, pp. 898–915, 2014.

[120] P. K. Mander, A. Jekabsons, and G. C. Brown, “Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase,” *The Journal of Immunology*, vol. 176, no. 2, pp. 1046–1052, 2006.

[121] R. Dringen, “Oxidative and antioxidative potential of brain microglial cells,” *Antioxidants and Redox Signaling*, vol. 7, no. 9-10, pp. 1223–1233, 2005.

[122] N. Shibata, A. Kakita, H. Takahashi et al., “Activation of signal transducer and activator of transcription-3 in the spinal cord of sporadic amyotrophic lateral sclerosis patients,” *Neurodegenerative Diseases*, vol. 6, no. 3, pp. 118–126, 2009.
[123] R. Zhang, K. G. Hadlock, H. Do et al., "Gene expression profiling in peripheral hilar mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS)," *Journal of Neuroimmunology,* vol. 230, no. 1-2, pp. 114–123, 2011.

[124] J. Kühle, R. L. P. Lindberg, A. Regeniter et al., "Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis," *European Journal of Neurology,* vol. 16, no. 6, pp. 771–774, 2009.

[125] M. Fiala, M. Chattopadhay, A. La Cava et al., "IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients," *Journal of Neuroinflammation,* vol. 7, article 76, 2010.

[126] M. Rentzos, A. Rombos, C. Nikolaou et al., "Interleukin-15 and Interleukin-12 are elevated in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis," *European Neurology,* vol. 63, no. 5, pp. 285–290, 2010.

[127] R. F. Itzhaki and M. A. Wozniak, "Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques," *The Journal of Pathology,* vol. 217, no. 1, pp. 131–138, 2009.

[128] I. Mori, Y. Kimura, H. Naiki et al., "Reactivation of HSV-1 in the brain of patients with familial Alzheimer's disease," *Journal of Medical Virology,* vol. 73, no. 4, pp. 605–611, 2004.

[129] L. Letenneur, K. Péris, H. Fleurry et al., "Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study," *PLoS ONE,* vol. 3, no. 11, Article ID e3637, 2008.

[130] S. Santana, M. Recuero, M. J. Bullido, F. Valdivieso, and J. Aluduo, "Herpes simplex virus type I induces the accumulation of intracellular β-amyloid in autophagic compartments and the inhibition of the non-amyloidogenic pathway in human neuroblastoma cells," *Neurobiology of Aging,* vol. 33, no. 2, pp. 430.e19–430.e33, 2012.

[131] R. Piacentini, L. Civitelli, C. Ripoli et al., "HSV-1 promotes Ca2+-mediated APP phosphorylation and Aβ accumulation in rat cortical neurons," *Neurobiology of Aging,* vol. 32, no. 12, pp. 2323.e13–2323.e26, 2011.

[132] G. De Chiara, M. E. Marcocci, L. Civitelli et al., "APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells," *PLoS ONE,* vol. 5, no. 11, Article ID e13989, 2010.

[133] R. Lerchundi, R. Neira, S. Valdivia et al., "Tau cleavage at D421 by caspase-3 is induced in neurons and astrocytes infected with Herpes Simplex Virus Type 1," *Journal of Alzheimer's Disease,* vol. 23, no. 3, pp. 513–520, 2011.

[134] E. Porcellini, I. Carbone, M. Ianni, and F. Licastro, "Alzheimer's disease gene signature says: beware of brain viral infections," *Immunity and Ageing,* vol. 7, article 16, 2010.

[135] M. E. Westarp, P. Ferrante, H. Perron, P. Bartmann, and H. H. Kornhuber, "Sporadic ALS/MND: a global neurodegeneration with retroviral involvement?" *Journal of the Neurological Sciences,* vol. 129, supplement, pp. 145–147, 1995.

[136] P. Ferrante, M. E. Westarp, R. Mancuso et al., "HTLV tax-rx DNA and antibodies in idiopathic amyotrophic lateral sclerosis," *Journal of the Neurological Sciences,* vol. 129, supplement, pp. 140–144, 1995.

[137] M. T. T. Silva, A. C. C. Leite, A. H. Alamy, L. Chimelli, M. J. Andrade-Serpa, and A. Q. C. Araújo, "ALS syndrome in HTLV-I infection," *Neurology,* vol. 65, no. 8, pp. 1332–1333, 2005.

[138] J. F. Zachary, T. V. Baszler, R. A. French, and K. W. Kelley, "Mouse Moloney leukemia virus infects microglia but not neurons even though it induces motor neuron disease," *Molecular Psychiatry,* vol. 2, no. 2, pp. 104–106, 1997.

[139] A. J. Steele, A. Al-Chalabi, K. Ferrante, M. E. Cudkowicz, R. H. Brown Jr., and J. A. Gascon, "Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives," *Neurology,* vol. 64, no. 3, pp. 454–458, 2005.

[140] M. V. Viola, M. Frazier, L. White, J. Brody, and S. Spiegelman, "RNA instructed DNA polymerase activity in a cytoplasmic particulate fraction in brains from Guamanian patients," *Journal of Experimental Medicine,* vol. 142, no. 2, pp. 483–494, 1975.

[141] R. F. Itzhaki and M. A. Wozniak, "Herpes simplex virus type 1 in Alzheimer's disease: the enemy within," *Journal of Alzheimer's Disease,* vol. 13, no. 4, pp. 393–405, 2008.

[142] M. A. Wozniak, A. P. Mee, and R. F. Itzhaki, "Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques," *The Journal of Pathology,* vol. 217, no. 1, pp. 131–138, 2009.
D. J. L. MacGowan, S. N. Scelsa, T. E. Imperato, K.-N. Liu, P. Baron, and B. Polsky, “A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS,” *Neurology*, vol. 68, no. 22, pp. 1944–1946, 2007.

A. L. McCormick, R. H. Brown Jr., M. E. Cudkowicz, A. Al-Chalabi, and J. A. Garson, “Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate,” *Neurology*, vol. 70, no. 4, pp. 278–283, 2008.

T. Alfaïhad and A. Nath, “Retroviruses and amyotrophic lateral sclerosis,” *Antiviral Research*, vol. 99, no. 2, pp. 180–187, 2013.

S. O. A. Oluwole, Y. Yao, S. Conradi, K. Kristensson, and H. Karlsson, “Elevated levels of transcripts encoding a human retroviral envelope protein (syncytin) in muscles from patients with motor neuron disease,” *Amyotrophic Lateral Sclerosis*, vol. 8, no. 2, pp. 67–72, 2007.

W. Li, M.-H. Lee, L. Henderson et al., “Human endogenous retrovirus-K contributes to motor neuron disease,” *Science Translational Medicine*, vol. 7, no. 307, p. 307ra153, 2015.

M. R. Ciriolo, A. T. Palamara, S. Incerpi et al., “Loss of GSH, oxidative stress, and decrease of intracellular pH as sequential steps in viral infection,” *The Journal of Biological Chemistry*, vol. 272, no. 5, pp. 2700–2708, 1997.

G. Gong, G. Waris, R. Tanveer, and A. Siddiqui, “Human hepatitis C virus NSSA protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 17, pp. 9599–9604, 2001.

P. Kaul, M. C. Biagioli, I. Singh, and R. B. Turner, “Rhinovirus-induced oxidative stress and interleukin-8 elaboration involves p47-phox but is independent of attachment to intercellular adhesion molecule-1 and viral replication,” *Journal of Infectious Diseases*, vol. 181, no. 6, pp. 1885–1890, 2000.

L. Nencioni, A. Iuvara, K. Aquilano et al., “Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2,” *The FASEB Journal*, vol. 17, no. 6, pp. 758–760, 2003.

E. Peterhans, “Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation,” *Journal of Nutrition*, vol. 127, supplement 5, pp. 9625–9655, 1997.

L. W. Enquist, P. J. Husak, B. W. Banfield, and G. A. Smith, “Infection and spread of alphaherpesviruses in the nervous system,” *Advances in Virus Research*, vol. 51, pp. 237–347, 1998.

S. Wickham, B. Lu, J. Ash, and D. J. Carr, “Chemokine receptor deficiency is associated with increased chemokine expression in the peripheral and central nervous systems and increased resistance to herpetic encephalitis,” *Journal of Neuroimmunology*, vol. 162, no. 1-2, pp. 51–59, 2005.

C. Nucci, A. T. Palamara, M. R. Ciriolo et al., “Imbalance in corneal redox state during herpes simplex virus 1-induced keratitis in rabbits. Effectiveness of exogenous glutathione supply,” *Experimental Eye Research*, vol. 70, no. 2, pp. 215–220, 2000.

A. T. Palamara, C.-F. Perno, M. R. Ciriolo et al., “Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type I replication,” *Antiviral Research*, vol. 27, no. 3, pp. 237–253, 1995.

T. Valyi-Nagy and T. S. Dermody, “Role of oxidative damage in the pathogenesis of viral infections of the nervous system,” *Histology and Histopathology*, vol. 20, no. 3, pp. 957–967, 2005.

S. J. Schachtele, S. Hu, M. R. Little, and J. R. Lokensgard, “Herpes simplex virus induces oxidative damage via microglial cell Toll-like receptor-2,” *Journal of Neuroinflammation*, vol. 7, article 35, 2010.